Dazzling Tecfidera makes its Indian debut
This article was originally published in Scrip
Biogen Idec has announced launch plans in India for Tecfidera (dimethyl fumarate) – the first oral therapy for remitting multiple sclerosis (RRMS) in the country.
You may also be interested in...
Eisai is straddling a mix of new opportunities for growth in India as it takes charge of sales of Biogen’s multiple sclerosis portfolio in the country and also eyes potential gains from its Japanese parent’s recent deal with Nichi-Iko.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.